Greetings,
Warm regards and the deepest gratitude to all of you who have shown trust and love for CELLONTECH.
In 2001, CELLONTECH developed and commercialized the first domestic biopharmaceutical in the field of life sciences, 'Chondron,' an autologous chondrocyte cell therapy. This marked the beginning of the era of biopharmaceuticals in South Korea
CELLONTECH has obtained patents for the manufacturing method of 'BioCollagen,' which is a core material in regenerative medicine. In 2008, it was listed in the US FDA's Drug Master File, allowing the commercialization of various regenerative medical products based on BioCollagen in areas such as cartilage, bone, connective tissues (ligaments-tendons), and skin. Additionally, CELLONTECH has secured global patent rights for 42 core technologies in 52 countries, leading the field of regenerative medicine.
As a company proud of being the First in Class in collagen-based medical devices, CELLONTECH carries the responsibility of opening the future of the bio powerhouse, South Korea, and firmly strives to provide opportunities for a better life for humanity and achieve lifelong health.
CEO Message
Thank you for visiting CELLONTECH, which opens the future of bio healthcare in South Korea.